Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids : patient-reported outcomes from two randomized monotherapy phase III trials. / Reich, K.; DeLozier, A. M.; Nunes, F. P.; Thyssen, J. P.; Eichenfield, L. F.; Wollenberg, A.; Ross Terres, J. A.; Watts, S. D.; Chen, Y. F.; Simpson, E. L.; Silverberg, J. I.

In: Journal of Dermatological Treatment, Vol. 33, No. 3, 2022, p. 1521-1530.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Reich, K, DeLozier, AM, Nunes, FP, Thyssen, JP, Eichenfield, LF, Wollenberg, A, Ross Terres, JA, Watts, SD, Chen, YF, Simpson, EL & Silverberg, JI 2022, 'Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials', Journal of Dermatological Treatment, vol. 33, no. 3, pp. 1521-1530. https://doi.org/10.1080/09546634.2020.1839008

APA

Reich, K., DeLozier, A. M., Nunes, F. P., Thyssen, J. P., Eichenfield, L. F., Wollenberg, A., Ross Terres, J. A., Watts, S. D., Chen, Y. F., Simpson, E. L., & Silverberg, J. I. (2022). Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. Journal of Dermatological Treatment, 33(3), 1521-1530. https://doi.org/10.1080/09546634.2020.1839008

Vancouver

Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. Journal of Dermatological Treatment. 2022;33(3):1521-1530. https://doi.org/10.1080/09546634.2020.1839008

Author

Reich, K. ; DeLozier, A. M. ; Nunes, F. P. ; Thyssen, J. P. ; Eichenfield, L. F. ; Wollenberg, A. ; Ross Terres, J. A. ; Watts, S. D. ; Chen, Y. F. ; Simpson, E. L. ; Silverberg, J. I. / Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids : patient-reported outcomes from two randomized monotherapy phase III trials. In: Journal of Dermatological Treatment. 2022 ; Vol. 33, No. 3. pp. 1521-1530.

Bibtex

@article{a757a19176f1498486fcd8526068c399,
title = "Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials",
abstract = "Background: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient{\textquoteright}s quality of life (QoL). Objective: To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient{\textquoteright}s assessment of disease severity. Methods: Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures. Results: At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline −36.6% and −29.4% vs. placebo (–12.0%), p≤.001 and p≤.05; BREEZE-AD2: −47.2% and −46.9% vs. placebo (–16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients{\textquoteright} assessment of AD severity and QoL than improvements in skin inflammation. Conclusions: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD. ClinicalTrials.gov identifiers: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).",
keywords = "Atopic dermatitis, clinical trial, eczema, JAK inhibitor",
author = "K. Reich and DeLozier, {A. M.} and Nunes, {F. P.} and Thyssen, {J. P.} and Eichenfield, {L. F.} and A. Wollenberg and {Ross Terres}, {J. A.} and Watts, {S. D.} and Chen, {Y. F.} and Simpson, {E. L.} and Silverberg, {J. I.}",
note = "Publisher Copyright: {\textcopyright} 2020 Eli Lilly and Company. Published with license by Taylor & Francis Group, LLC.",
year = "2022",
doi = "10.1080/09546634.2020.1839008",
language = "English",
volume = "33",
pages = "1521--1530",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids

T2 - patient-reported outcomes from two randomized monotherapy phase III trials

AU - Reich, K.

AU - DeLozier, A. M.

AU - Nunes, F. P.

AU - Thyssen, J. P.

AU - Eichenfield, L. F.

AU - Wollenberg, A.

AU - Ross Terres, J. A.

AU - Watts, S. D.

AU - Chen, Y. F.

AU - Simpson, E. L.

AU - Silverberg, J. I.

N1 - Publisher Copyright: © 2020 Eli Lilly and Company. Published with license by Taylor & Francis Group, LLC.

PY - 2022

Y1 - 2022

N2 - Background: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient’s quality of life (QoL). Objective: To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient’s assessment of disease severity. Methods: Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures. Results: At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline −36.6% and −29.4% vs. placebo (–12.0%), p≤.001 and p≤.05; BREEZE-AD2: −47.2% and −46.9% vs. placebo (–16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients’ assessment of AD severity and QoL than improvements in skin inflammation. Conclusions: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD. ClinicalTrials.gov identifiers: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).

AB - Background: Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient’s quality of life (QoL). Objective: To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient’s assessment of disease severity. Methods: Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures. Results: At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline −36.6% and −29.4% vs. placebo (–12.0%), p≤.001 and p≤.05; BREEZE-AD2: −47.2% and −46.9% vs. placebo (–16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients’ assessment of AD severity and QoL than improvements in skin inflammation. Conclusions: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD. ClinicalTrials.gov identifiers: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).

KW - Atopic dermatitis

KW - clinical trial

KW - eczema

KW - JAK inhibitor

U2 - 10.1080/09546634.2020.1839008

DO - 10.1080/09546634.2020.1839008

M3 - Journal article

C2 - 33222559

AN - SCOPUS:85096622620

VL - 33

SP - 1521

EP - 1530

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 3

ER -

ID: 320676955